By Revenue, Pfizer is the Winner in the COVID Vaccine Wars
Posted on 02/08/2022
Pfizer Inc. projects they will generate record-high revenue in 2022, expecting to sell US$ 32 billion of its COVID-19 mRNA shots and US$ 22 billion of its antiviral coronavirus treatment pill Paxlovid this year. Pfizer forecasts US$ 98 billion to US$ 102 billion in sales for 2022, and adjusted earnings per share of $6.35 to $6.55. Angela Hwang, Head of Biopharmaceuticals at Pfizer, disclosed that the drug company is an active discussions with over 100 countries around the world on Paxlovid. Pfizer believes a phase two or three study of an mRNA flu vaccine could start this year and conclude in 2023.
The New York Times reported that pharma giant Johnson & Johnson has halted production of its single-dose COVID-19 vaccine. In 2021, Johnson & Johnson closed its COVID-19 vaccine production at a plant in Leiden, Netherlands. Johnson & Johnson has focused on using the Leiden plant for experimental and potentially more profitable drug that could protect against an unrelated respiratory virus. The pause in COVID vaccine production is reportedly temporary.